Share >  
Share
Share on Tumblr

Betapharm

News »

   latest by relevance
To improve market share, position in Germany: Dr Reddy's
May 13, 2011 at 18:35 | Source: CNBC-TV18
GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.
Dr Reddy's rejuvenation
Jan 17, 2011 at 12:35 | Source: Forbes India
Audacity pushed it from its perch as one of Indias top drug makers. Realism is helping it make a comeback.
See robust growth in US, Russia in 2010: DRL
Jan 20, 2010 at 18:01 | Source: CNBC-TV18
Dr Reddy's Labs has reported a consolidated net loss of Rs 233 crore in the quarter ended December 2009 as against a profit of Rs 192.4 crore in the same period last year. In an interview with CNBC-TV18, GV Prasad, Vice Chairman and CEO, Dr. Reddy's Labs spoke about the quarter gone by and gave his perspective on the road ahead.
Dr Reddys sees better show from Betapharm this year
Jul 08, 2009 at 08:52 | Source: Business Line
Pharma major Dr Reddys Laboratories Ltd is expecting its German arm, Betapharm, to perform better during the current financial year.
DRL arm Betapharm bags five contracts from A-O-K
May 08, 2009 at 09:31 | Source: CNBC-TV18
Indian drug maker Dr Reddy's German subsidiary Betapharm has received five contracts for bulk supply of drugs to German insurer A-O-K. These are five of the eight contracts which it won in December 2008 but were put on hold after there were complaints against the tender process.
Dr Reddys to exit small generic drug markets abroad
Mar 20, 2009 at 08:34 | Source: Business Line
Pharma major Dr Reddys Laboratories Ltd has decided to exit from the small distributor-driven markets in its global generics business. It would now focus more on key markets.

Videos »
To improve market share, position in Germany: Dr Reddy's
See robust growth in US, Russia in 2010: DRL
DRL arm Betapharm bags five contracts from A-O-K
Balaglitazone R&D costs to be shared by co-developer: DRL
Ranbaxy: In top 5 pharma club by 2012?
more »

Photos »

  /  
News across the web »
Sale of key generic in US, weak rupee help Dr Reddy's Labs
Windfall sales from olanzapine (the generic version of Eli Lilly's Zyprexa 20 mg used in the treatment of schizophrenia and bipolar disorder) and rupee depreciation helped Dr Reddy's Laboratories pos...
Feb 04, 2012 at 21:42 | Source: The Hindu BusinessLine
Eurozone impact on India Inc
Over the past decade, Indian companies have been amassing assets across Europe. Since 2006, Indian firms have spent $37.9 billion on European acquisitions, according to data gathered for Business Lin...
Dec 11, 2011 at 21:12 | Source: The Hindu BusinessLine
We expect growth in the US to return this quarter
In an interview, G.V. Prasad, vice-chairman and chief executive officer of Dr Reddy’s Laboratories Ltd spoke about the quarter gone by and the road ahead Sunita Nagpal / CNBC-TV18 Email Print del.ic...
Jan 21, 2010 at 08:06 | Source: Livemint-Money Commodities
Alliance with GSK will not boost sales immediately
Drug maker Dr Reddy’s Laboratories Ltd is launching Prilosec, a product used to treat stomach ulcers and heartburn, in the US market Udayan Mukherjee and Mitali Mukherjee / CNBC-TV18 Email Print del...
Dec 15, 2009 at 21:55 | Source: Livemint-Money Commodities
more »
Related News »
Accumulate Dr Reddys Labs; target of Rs 1938: Dolat Capital
Notably, dependence on Betapharm has reduced significantly (5% of sales), and is unlikely to be a further drag on overall financials. A string of product launches in US and other generic markets, coupled with healthy traction in the PSAI segment ...
May 18, 2012 at 06:18 | Source: MoneyControl.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window